Literature DB >> 6181723

Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induced pulmonary fibrosis in the rat.

R S Thrall, R W Barton, D A D'Amato, S B Sulavik.   

Abstract

The purpose of this study was to analyze the cellular components of bronchoalveolar lavage fluid throughout the development of bleomycin-induced pulmonary fibrosis in the rat. Animals were killed and lavaged at various times after the administration of a single intratracheal injection of bleomycin. The results demonstrate that a significant influx of inflammatory cells appear in the lavage fluid as early as Day 1 after bleomycin treatment. Polymorphonuclear leukocytes are the first cells to appear and significant concentrations persist for as long as 1 month after bleomycin treatment. There is a very transient yet significant influx of eosinophils on Day 7 after bleomycin treatment. Lymphocytes are present from 3 to 14 days after bleomycin treatment; greater than 97% are T-cells and less than 3% are B-cells. There is a 1:1 ratio of W3/25+ cells (helper cell activity) to OX8+ cells (suppressor cell activity) comprising the lymphocyte population. The blood and lymphoid tissue of these animals contain a normal 2:1 ratio of these subsets. The data demonstrate that specific T-cell populations are present in the air spaces of the lung in response to bleomycin-induced pulmonary fibrosis in this model.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181723     DOI: 10.1164/arrd.1982.126.3.488

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  26 in total

1.  Stimulation of rat endothelial cell transforming growth factor-beta production by bleomycin.

Authors:  S H Phan; M Gharaee-Kermani; F Wolber; U S Ryan
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

2.  Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Authors:  J G Hay; P L Haslam; A Dewar; B Addis; M Turner-Warwick; G J Laurent
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

3.  Effects of a calmodulin inhibitor on bleomycin-induced lung inflammation in hamsters. Biochemical, morphometric, and bronchoalveolar lavage data.

Authors:  J M Nakashima; D M Hyde; S N Giri
Journal:  Am J Pathol       Date:  1986-09       Impact factor: 4.307

4.  The effects of bleomycin on alveolar macrophage growth factor secretion.

Authors:  E M Denholm; S H Phan
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

5.  Bronchoalveolar lavage cell populations in bleomycin lung toxicity.

Authors:  D A White; M G Kris; D E Stover
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

6.  Early biochemical reactions in the lung of sheep exposed to asbestos: evidence for cyclic AMP accumulation in bronchoalveolar lavage fluids.

Authors:  I Lemaire; P Sirois; M Rola-Pleszczynski; S Massé; R Bégin
Journal:  Lung       Date:  1981       Impact factor: 2.584

7.  Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats.

Authors:  G Westergren-Thorsson; J Hernnäs; B Särnstrand; A Oldberg; D Heinegård; A Malmström
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 8.  New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease.

Authors:  T D Tetley
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

9.  Changes in distribution, morphology, and tumor necrosis factor-alpha secretion of alveolar macrophage subpopulations during the development of bleomycin-induced pulmonary fibrosis.

Authors:  M P Everson; D B Chandler
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

10.  NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury.

Authors:  Louise Hecker; Ragini Vittal; Tamara Jones; Rajesh Jagirdar; Tracy R Luckhardt; Jeffrey C Horowitz; Subramaniam Pennathur; Fernando J Martinez; Victor J Thannickal
Journal:  Nat Med       Date:  2009-08-23       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.